A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Kura Oncology, Inc.
7 Hills Pharma, LLC
Tel-Aviv Sourasky Medical Center
Xencor, Inc.
Psyence Australia Pty Ltd
Dana-Farber Cancer Institute
Tizona Therapeutics, Inc
Essen Biotech
A2 Biotherapeutics Inc.
Memorial Sloan Kettering Cancer Center
University of Nebraska
Adela, Inc
Elephas
UNC Lineberger Comprehensive Cancer Center
Elephas
Palo Alto Veterans Institute for Research
Degron Therapeutics Co.
University Health Network, Toronto
Dana-Farber Cancer Institute
Massive Bio, Inc.
Hadassah Medical Organization
A2 Biotherapeutics Inc.
University of California, San Francisco
Western University, Canada
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
Columbia University
Chinese University of Hong Kong
Molecure S.A.
Centre Georges Francois Leclerc
University Health Network, Toronto
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
European Organisation for Research and Treatment of Cancer - EORTC
University of Sydney
Second Affiliated Hospital of Guangzhou Medical University
N.N. Petrov National Medical Research Center of Oncology
IRCCS San Raffaele
Shanghai Yunying Medical Technology
Hospices Civils de Lyon